PAD 133 (Hydrochlorothiazide and moexipril hydrochloride 12.5 mg / 7.5 mg)
Pill imprint PAD 133 has been identified as Hydrochlorothiazide and moexipril hydrochloride 12.5 mg / 7.5 mg.
Hydrochlorothiazide/moexipril is used in the treatment of high blood pressure and belongs to the drug class ACE inhibitors with thiazides. There is positive evidence of human fetal risk during pregnancy. Hydrochlorothiazide/moexipril 12.5 mg / 7.5 mg is not a controlled substance under the Controlled Substance Act (CSA).
- Imprint:
- PAD 133
- Strength:
- 12.5 mg / 7.5 mg
- Color:
- Yellow
- Shape:
- Elliptical / Oval
- Availability:
- Prescription only
- Drug Class:
- ACE inhibitors with thiazides
- Pregnancy Category:
- D - Positive evidence of risk
- CSA Schedule:
- Not a controlled drug
- Manufacturer:
- Paddock Laboratories, Inc.
- National Drug Code (NDC):
- 00574-0133
- Inactive Ingredients:
- lactose
magnesium oxide
crospovidone
magnesium stearate
povidone
silicon dioxide
hypromelloses
titanium dioxide
polyethylene glycol 400
ferric oxide red
More about hydrochlorothiazide/moexipril
Consumer resources
- Hydrochlorothiazide/moexipril
- Moexipril/hydrochlorothiazide
- Hydrochlorothiazide and moexipril
- Moexipril and hydrochlorothiazide (Advanced Reading)
- Other brands: Uniretic
Professional resources
Related treatment guides
Disclaimer:
Every effort has been made to ensure that the information provided is accurate, up-to-date, and complete, but no guarantee is made to that effect. If you have questions about the drugs you are taking, check with your doctor, nurse or pharmacist.
Copyright 2016 Drugs.com, National Library of Medicine, Truven Health Analytics and Cerner Multum, Inc. All Rights Reserved.
